NCT07512154Recruiting
Precision Radiotherapy Enabled by Molecular MRI
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for radiotherapy of brain tumors.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 30 Mar 2026
- Start date
- 29 Apr 2026
- Primary completion date
- 31 May 2031
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Diseases
- Glioblastoma
- NCT number
- NCT07512154
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 29 Apr 2026 to the primary completion date, 31 May 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients may not be receiving any other investigational cancer treatment agents at the time of enrollment.
- Patients may not have previously been treated with an overlapping course of radiotherapy to the brain.
Other illness
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Other
- Patients who are unable to receive MRIs will be excluded from the study.
- Pregnant and/or breastfeeding women are excluded. Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 12 weeks after the study are excluded. Male subjects must also agree to use effective contraception for the same period as above.
Who the study is looking for
- Histologic confirmation of glioblastoma or grade 4 astrocytoma
- Age \>18
- KPS at least 60
- Patients must have normal organ and marrow function as defined below:
- leukocytes \>3,000/mcL
- absolute neutrophil count \>1,500/mcL
- platelets \>100,000/mcL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) \<2.5
- institutional upper limit of normal
- creatinine within normal institutional limits OR creatinine clearance \>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
- Patients of child-bearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child.
- Ability to understand and the willingness to sign a written informed consent document.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins University Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.